JPRN-UMIN000007958招募中2 期
Intraretinal vessel treatment for central retinal vein occlusion - IVTEC
Intraretinal vessel treatment for central retinal vein occlusion study team0 个研究点目标入组 10 人开始时间: 2012年5月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Key exclusion criteria included CRVO with neovascularization, any previous treatment for CRVO, intraocular surgery during the previous 3 months, vascular retinopathy arising from other causes, glaucoma with an advanced visual field defect or uncontrolled ocular hypertension (25 mmHg) despite full therapy, and myocardial infarction or stroke during the last 12 months. All the participants provided their written informed consent.
研究者
相似试验
进行中（未招募）
1 期
Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). - Lucentis in CRVOThis case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.MedDRA version: 12.1Level: LLTClassification code 10007972Term: Central retinal vein occlusionMedDRA version: 12.1Level: LLTClassification code 10054467Term: Macular edemaEUCTR2009-017782-30-ATMedizinische Universität Graz, Universitäts-Augenklinik
进行中（未招募）
1 期
Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusiomacular edema secondary to branch retinal vein occlusion (BRVO)MedDRA version: 18.1Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 100000004853MedDRA version: 18.1Level: LLTClassification code 10038906Term: Retinal vein branch occlusionSystem Organ Class: 100000004853EUCTR2012-005439-10-DEniversity of Leipzig Ritterstr. 26, 04109 Leipzig18
已完成
1 期
Treatment of macular edema secondary to central vein occlusiocentral vein occlusion.Other retinal vascular occlusionsIRCT201011295270N1Banco de Olhos de Sorocaba15
进行中（未招募）
不适用
Treatment of a chorioretinal disease characterized by alterations in the elastic lamina of the Bruch's membrane, and which typically manifest themselves as streaks radial departure from the optic nerveEUCTR2014-000986-30-ITIRCCS Ospedale San Raffaele U.O. Oculistica
已完成
不适用
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularizationJPRN-UMIN000016870agoya City University Graduate School of Medicine20